VCWA
NAUT icon

Vanguard Capital Wealth Advisors’s Nautilus Biotechnolgy NAUT Stock Holding History

Vanguard Capital Wealth Advisors’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,500
Closed -$938 – 150
2023
Q2 		$938 Buy
+2,500
New +$7.2K ﹤0.01% 140

Other funds holding NAUT

CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
ST
Sentinel Trust Houston, Texas $1.13B AUM 24.31% 1-Year Est. Return
HC
Hillman Company Pittsburgh, Pennsylvania $283M AUM 23.82% 1-Year Est. Return
CA
Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CG
Caprock Group Boise, Idaho $5.22B AUM 42.47% 1-Year Est. Return
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.79B AUM 27.94% 1-Year Est. Return
PCM
Presidio Capital Management San Diego, California $400M AUM 22.73% 1-Year Est. Return

Vanguard Capital Wealth Advisors's NAUT Position: Q2 2026 in Review

Vanguard Capital Wealth Advisors held its Nautilus Biotechnolgy (NAUT) position steady in Q2 2026 at 13,000 shares worth $24.3K. The position accounts for 0.02% of the portfolio, ranked #130.

Vanguard Capital Wealth Advisors first reported a position in NAUT in Q4 2021 and has held it in 19 quarters since. The position peaked at $235K in Q4 2021. 24 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

  • Vanguard Capital Wealth Advisors held 13,000 shares of Nautilus Biotechnolgy worth $24.3K as of Q2 2026.
  • Vanguard Capital Wealth Advisors left its Nautilus Biotechnolgy share count unchanged in Q2 2026.
  • Nautilus Biotechnolgy made up 0.02% of Vanguard Capital Wealth Advisors's portfolio in Q2 2026, its #130 holding.
  • Vanguard Capital Wealth Advisors first reported a position in Nautilus Biotechnolgy in Q4 2021 and has held it in 19 quarters since.
  • Vanguard Capital Wealth Advisors's Nautilus Biotechnolgy position peaked at $235K in Q4 2021.
  • 24 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on Vanguard Capital Wealth Advisors's 13F filing for Q2 2026, filed 23 Jul 2026.